Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168402 | 0.84 | KMT2A (0.54) | KMT2AL3MBTL1KDM4EUBE2NMAPT | |
| SCHEMBL19778587 | 0.84 | KMT2A (0.54) | KMT2AL3MBTL1KDM4EUBE2NMAPT | |
| SCHEMBL31031032 | 0.84 | KMT2A (0.45) | KMT2AKDM4EMEN1CYP2C9MAPT | |
| SCHEMBL1063920 | 0.83 | CYP2C9 (0.61) | KMT2AL3MBTL1KDM4ECYP2C9MAPT | |
| SCHEMBL15754423 | 0.82 | RPA1 (0.50) | KMT2AL3MBTL1KDM4EMEN1ATM | |
| SCHEMBL14812729 | 0.81 | KMT2A (0.44) | KMT2AMEN1ATMCYP2C9 | |
| SCHEMBL2360605 | 0.81 | UBE2N (0.48) | KMT2ACYP2C9UBE2NMAPTNOTUM | |
| SCHEMBL15755051 | 0.80 | KEAP1 (0.47) | KMT2AMEN1CYP2C9NOTUM | |
| SCHEMBL28291686 | 0.80 | KMT2A (0.50) | KMT2AL3MBTL1KDM4EMEN1UBE2N | |
| SCHEMBL1816062 | 0.80 | CYP2C9 (0.45) | KMT2AL3MBTL1KDM4ECYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103596937-B | Substituted benzamide derivatives | 霍夫曼-拉罗奇有限公司 | 2016-06-29 | — | — | CN | claimed |
| EP-2718271-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-08-12 | — | — | EP | claimed |
| US-9029370-B2 | Substituted benzamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-05-12 | — | — | US | claimed |
| EP-2718271-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | claimed |
| WO-2012168265-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | claimed |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-12-13 | — | — | US | claimed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-117143019-A | As beta 2 Pyrazole amide derivatives of allosteric antagonists of the adrenergic receptors | 常州大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-117088861-A | 2-substituted aryl-oxazolin-4-one derivative and application thereof | 浙江大学 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023183444-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-103596937-A | Substituted benzamide derivatives | HOFFMANN LA ROCHE | 2014-02-19 | — | — | CN | disclosed |
| US-20120316172-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2012168265-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168260-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-12-13 | — | — | US | disclosed |
| CN-1342147-A | Nitrooxyderivatives having anti-inflammatory, analgesic and antithrombotic activity | NICOX SA (FR) | 2002-03-27 | — | — | CN | disclosed |
| CN-1050382-A | Pyrazole derivatives and preparation method thereof and medicinal compositions | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | KMT2A 2661/4885L3MBTL1 2538/4885KDM4E 2695/4885 |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | NPY4R, PER2, NPY1R | KMT2A 1243/4885L3MBTL1 2952/4885KDM4E 1330/4885 |
| US-20120316172-A1 | PYRAZOLE DERIVATIVES | TAAR1, TAAR5, NPY1R | KMT2A 2339/4885L3MBTL1 3584/4885KDM4E 3125/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | KMT2A 4596/4885L3MBTL1 4266/4885KDM4E 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.